# Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

> **NCT04638634** · PHASE1 · TERMINATED · sponsor: **CSL Behring** · enrollment: 12 (actual)

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)

## Interventions

- **BIOLOGICAL:** CSL760

## Key facts

- **NCT ID:** NCT04638634
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-02
- **Primary completion:** 2021-06-09
- **Final completion:** 2021-06-09
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** For business reasons, not a safety issue
- **Last updated:** 2021-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638634, "Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04638634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*